The findings reported by Kato et al. are setting the stage for the use of the G9a/GLP inhibitors as an opportunity to evaluate G9a inhibition as a therapeutic avenue to target colorectal cancer-initiating cells in vivo. The gene discussed is EHMT2; the disease is colorectal cancer.